|1.||Bullock, C: 1 article (01/2015)|
|2.||Chapman, R J: 1 article (01/2015)|
|3.||Paton, K: 1 article (01/2015)|
|4.||Sagar, D R: 1 article (01/2015)|
|5.||Walsh, D A: 1 article (01/2015)|
|6.||Hathway, G J: 1 article (01/2015)|
|7.||Woodhams, S: 1 article (01/2015)|
|8.||Chapman, V: 1 article (01/2015)|
|9.||Burston, J J: 1 article (01/2015)|
|10.||Kelly, S: 1 article (01/2015)|
10/01/2010 - "These data indicate that TRPV1 is involved in the pathogenesis of visceral hypersensitivity and that JNJ-17203212 may be a potential therapeutic agent for functional bowel disorders characterized by abdominal hypersensitivity, such as irritable bowel syndrome."
10/01/2010 - "In both groups, VMR to CRD was significantly reduced by administration of JNJ-17203212 at 30 mg/kg. The results of this study show that the selective TRPV1 antagonist, JNJ-17203212, reduces sensitivity to luminal distension in both an acute, noninflammatory and a chronic, post-inflammatory rodent model of colonic hypersensitivity. "
10/01/2010 - "A novel TRPV1 receptor antagonist JNJ-17203212 attenuates colonic hypersensitivity in rats."
11/01/2007 - "The purpose of this study was to characterize a TRPV1 antagonist, 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), against the guinea pig TRPV1 receptor in vitro followed by a proof-of-principle study in an acid-induced model of cough. "
11/01/2007 - "Last, JNJ17203212 dose-dependently produced antitussive efficacy in citric acid-induced experimental cough in guinea pigs. "
11/01/2007 - "Intraperitoneal administration of 20 mg/kg JNJ17203212 achieved a maximal plasma exposure of 8.0 +/- 0.4 microM, and it attenuated capsaicin evoked coughs with similar efficacy to codeine (25 mg/kg). "
|3.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
01/01/2015 - "Local administration of JNJ-17203212 reversed this sensitisation of joint afferents and inhibited pain behaviour (weight-bearing asymmetry), to a comparable extent as systemic JNJ-17203212, in this model of OA pain, but did not alter core body temperature. "
01/01/2015 - "Effects of peripheral administration of the TRPV1 receptor antagonist JNJ-17203212 on afferent fibre activity, pain behaviour and core body temperature were investigated. "
|4.||Citric Acid (Citrate)
|5.||Codeine (Codeine Phosphate)